TheEdgeResearch
Home / Stocks / TRIB

Trinity Biotech plc (TRIB)

NASDAQ Healthcare Medical - Diagnostics & Research
$12.75 ▼ -4.71%
Market Cap
$258.2M
Sector
Healthcare
Industry
Medical - Diagnostics & Research
Beta
0.99
52-Wk Range
7.94-103.2
CEO
John Gillard
Country
IE
Currency
USD

Trinity Biotech plc operates in the Medical - Diagnostics & Research industry of the Healthcare sector, headquartered in Bray, WW, IE. The stock last traded at $12.75, down 4.71% on the session, giving a market capitalisation of $258.2M. On trailing twelve-month figures it carries a trailing P/E of -0.21, a net margin of -85.3%. Its beta of 0.99 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
-0.21
Price / Sales
5.89
Price / Book
-0.11
EV / EBITDA
-45.65
Gross margin
35.4%
Operating margin
-25.7%
Net margin
-85.3%
Return on equity
Debt / equity
-1.92
Current ratio
0.25
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
NASDAQ Global Select
Employees
287
IPO date
1992-10-21
Headquarters
Bray, WW, IE
About Trinity Biotech plc

Trinity Biotech plc, an Irish enterprise founded in 1992 and headquartered in Bray, is engaged in the acquisition, development, manufacturing, and global distribution of medical diagnostic solutions. The company's reach extends to the Americas, Africa, Asia, and Europe, catering to both clinical laboratory and point-of-care diagnostic markets. Its extensive range of clinical laboratory offerings encompasses diagnostic tests and specialized instrumentation for identifying numerous infectious diseases. These include Lyme disease, sexually transmitted infections like syphilis and herpes, SARS-CoV-2, and a variety of viral pathogens such as Epstein Barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, and varicella. Additionally, Trinity Biotech provides in-vitro diagnostic products centered on haemoglobin A1c for the crucial monitoring, diagnosis, and risk assessment of diabetes. The company's product development incorporates diverse assay formats, including immunofluorescence, enzyme-linked immunosorbent (ELISA), Western blot, and line immunoassays. It also supplies a suite of reagent products, including ACE, bile acids, lactate, oxalate, and glucose-6-phosphate dehydrogenase, vital for diagnosing liver and kidney disorders, as well as haemolytic anaemia. Beyond diagnostics, Trinity Biotech serves the life sciences industry and research facilities by supplying raw materials. The company's customer base comprises public health authorities, non-governmental organizations, and both clinical and reference laboratories. Its products are distributed through a dedicated direct sales force, complemented by a broad network of independent distributors and strategic partnerships.

Comparable companies

Trinity Biotech plc is most often compared with the following Healthcare names:

ADVBBGLCCHEKEVGNGBSMRKRSINTSNSETNONXAIR
More research on TRIB
TRIB technical analysis TRIB TheEdge Score Compare against peers
Open full interactive analysis & DCF →